GE HealthCare Posts $21.8B Backlog, Unveils AI LOGIQ Ultrasound
GE HealthCare closed Q4 2025 with a record $21.8 billion backlog (up $2 billion year-over-year), a 1.06 book-to-bill ratio, double-digit Pharmaceutical Diagnostics growth and mid-single-digit Imaging gains. It plans to acquire Intelerad to bolster cloud imaging, launched AI-powered LOGIQ ultrasound with Verisound Digital, and secured FDA 510(k) for three MR innovations.
1. Q4 Performance and Backlog
GE HealthCare ended Q4 2025 with a record $21.8 billion backlog, up $2 billion year-over-year, and achieved a book-to-bill ratio of 1.06. The segment delivered double-digit organic growth in Pharmaceutical Diagnostics and mid-single-digit gains in Imaging and Advanced Visualization Solutions.
2. Strategic Acquisitions and Partnerships
The company agreed to acquire Intelerad to expand its cloud-enabled enterprise imaging capabilities across care settings and signed a seven-year, multi-solution deal with the University of Rochester Medical Center for AI-enabled equipment, radiopharmaceutical production, and patient-monitoring systems.
3. New Product Launch: AI LOGIQ Ultrasound Systems
GE HealthCare introduced next-generation LOGIQ ultrasound platforms featuring AI-powered image analysis and Verisound Digital technology focused on liver disease assessment and streamlined workflows. These systems aim to enhance diagnostic precision and reduce exam times in clinical settings.
4. Regulatory Approvals and Innovation Pipeline
The firm secured FDA 510(k) clearance for three new SIGNA MR systems—Sprint with Freelium, Bolt, and One—and partnered with Diagnoly to apply AI to fetal ultrasound assessments. New products now account for 55% of revenues, supporting its D3 precision care strategy.